# Dalpiciclib in HR+/HER2- ABC

> **NCT06301438** · — · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 103 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** dalpiciclib

## Key facts

- **NCT ID:** NCT06301438
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-03
- **Primary completion:** 2027-01
- **Final completion:** 2028-12
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06301438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06301438, "Dalpiciclib in HR+/HER2- ABC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06301438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*